How does asciminib compare with TKIs in CML?
Patients with newly diagnosed chronic myeloid leukemia (CML) showed better response rates and higher safety when treated with asciminib compared with standard tyrosine
Acute Myeloid Leukemia
Leukemia
News
Society Updates
SOHO Announces SEHH/SETH Joint Session With Dr. Garcia-Manero
The Society of Hematologic Oncology (SOHO) will be holding a joint session with two Spain-based hematology societies: la Sociedad Española de Hematología y
Myelodysplastic Syndromes
News
Primary analysis finds luspatercept reduces transfusion dependence in lower-risk MDS
Luspatercept is more effective than epoetin alfa in achieving transfusion independencin anemia patients with lower-risk myelodysplastic syndromes (MDS), according to a primary analysis
Acute Lymphoblastic Leukemia
Leukemia
Salvage therapies show high remission rate in relapsed Ph+ ALL
Patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) who relapsed after frontline ponatinib-based therapies had a high response rate to salvage treatments,
Education Resources
The Twelfth Annual Meeting of the Society of Hematologic Oncology
Meet-the-Professor session with Natalie Callander, MD
This Meet-the-Professor session in multiple myeloma is delivered by Natalie Callander, MD, of the University of Wisconsin. Dr. Callander as part of the
Education Resources
This scientific session on transplant in CML is delivered by Jerald Radich, MD, of the Fred Hutchinson Cancer Research Center as part of the Twelfth Annual Meeting of the Society of Hematologic Oncology (SOHO 2024) held in Houston, Texas, in September 2024.
https://www.youtube.com/watch?v=_bEs0Bmcj4o For more educational resources, become a SOHO member for free at soho.click/join.
Meeting News
The Twelfth Annual Meeting of the Society of Hematologic Oncology
Video Interviews
Nitin Jain, MD, on Innovative Therapies in CLL
Hagop Kantarjian, MD, professor and chair in the Department of Leukemia at the University of Texas MD Anderson Cancer Center, and Nitin Jain,
Myeloproliferative Neoplasms
Primary Myelofibrosis
Fedratinib effective in patients with myelofibrosis previously treated with ruxolitinib
Results from the FREEDOM2 phase 3 trial supported the efficacy of fedratinib versus best available therapy (BAT) in patients with myelofibrosis previously treated
Lymphoma
Mantle Cell Lymphoma
Acalabrutinib granted Priority Review for patients with untreated MCL
The US Food and Drug Administration (FDA) has granted Priority Review status to the supplemental New Drug Application (sNDA) for acalabrutinib, a Bruton
Meeting News
Momelotinib has greater anemia-related benefits in myelofibrosis
Momelotinib was associated with greater anemia-related benefits in patients with myelofibrosis, according to an analysis presented at the 12th Annual Meeting of the
